Structure
(Lopinavir Metabolite M-1, CAS 192725-39-6)
sFTX-3.3 biochemical
sFTX-3.3
Purity
98%
Synonyms
sFTX-3.3; N/A; sFTX-3.3 biochemical
Purity/Purification
98%
CAS
141997-14-0
Targets&IC50
P-type calcium channel:0.24 mM (IC50), N-Type Ca 2+ Channel:0.70 mM (IC50)
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
In vitro
sFTX-3.3 (100 uM) reduces the duration of the slow component of presynaptic calcium currents by about 50% of the control and also reduces presynaptic sodium current by approximately 20% of the control. sFTX-3.3 (100 uM) reduces whole-cell sodium current recorded from SK.N.SH cells by approximately 15%[3].
Preparation and Storage
Powder: -20 degree C for 3 years
In solvent: -80 degree C for 2 years
In solvent: -80 degree C for 2 years
Structure
(Lopinavir Metabolite M-1, CAS 192725-39-6)
Structure
(Lopinavir Metabolite M-1, CAS 192725-39-6)
Structure
(Lopinavir Metabolite M-1, CAS 192725-39-6)
Structure
(Lopinavir Metabolite M-1, CAS 192725-39-6)
Related Product Information for sFTX-3.3 biochemical
sFTX-3.3 is a Ca 2+ channel antagonist with IC 50 s of approximately 0.24 mM and 0.70 mM against P-type and N-type channels.
References
1. Sham HL, et, al. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4; 11(11): 1351-3.
2. Kumar GN, et, al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug; 27(8): 902-8.
2. Kumar GN, et, al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug; 27(8): 902-8.
Similar Products
Product Notes
The sFTX-3.3 (Catalog #AAA227669) is a Biochemical and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "sFTX-3.3, Biochemical" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.